Table 1.
|
Patients, number (%) |
CellSearch® images, number (%) |
---|---|---|
n = 131 (100%) | n = 272 (100%) | |
Dataset |
|
|
Institute Jules Bordet |
34 (26) |
60 (22) |
Institute Curie |
60 (46) |
114 (42) |
University of Hamburg |
37 (28) |
98 (36) |
Age, years |
|
|
≤50 |
58 (44) |
108 (40) |
>50 |
66 (51) |
147 (54) |
Unknown |
7 (5) |
17 (6) |
ER |
|
|
Negative |
54 (41) |
106 (39) |
Positive |
68 (52) |
139 (51) |
Unknown |
9 (7) |
27 (10) |
HER2 |
|
|
Negative |
103 (79) |
193 (71) |
Positive |
15 (11) |
44 (16) |
Unknown |
13 (10) |
35 (13) |
Histology grade |
|
|
1 |
5 (4) |
6 (2) |
2 |
46 (35) |
85 (31) |
3 |
69 (53) |
147 (54) |
Unknown |
11 (8) |
34 (13) |
Histology |
|
|
Ductal |
99 (76) |
202 (74) |
Lobular |
10 (8) |
12 (4) |
Other |
7 (5) |
18 (7) |
Unknown |
15 (11) |
40 (15) |
Stage |
|
|
M0 |
109 (83) |
215 (79) |
M1 |
22 (17) |
57 (21) |
CTC count
1
|
|
|
<5 CTCs |
90 (69) |
150 (55) |
≥5 CTCs |
40 (30) |
120 (44) |
Unknown |
2 (1) |
2 (1) |
Systemic therapy before blood sample collection
2
|
|
|
No |
87 (65) |
168 (62) |
Yes |
31 (24) |
62 (23) |
Unknown | 15 (11) | 42 (15) |
1One patient with two samples (<5 CTCs and ≥ 5CTCs) was included; 2two patients with samples before and after treatment were included. ER, estrogen receptor; CTC, circulating tumor cell; M0, non-metastatic; M1, metastatic.